Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clot patients on heart meds: safer combo found?

NCT ID NCT05627375

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks for the best way to treat people who have a blood clot (like in the leg or lung) and also take daily aspirin or similar drugs for heart disease. Both conditions need blood thinners, but taking them together raises the risk of dangerous bleeding. The trial will compare different treatment plans in 1,400 adults to find which one prevents new clots and heart problems while causing the least bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Signed informed consent * Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb. * Indication of full-dose anticoagulant therapy for at least 3 months. * Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis * Life expectancy more than 3 months * Social security affiliation Exclusion Criteria: * Unable to give informed consent * Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg * Anticoagulation for more than 5 days prior to randomization * Active pregnancy or expected pregnancy or no effective contraception * Isolated distal deep vein thrombosis * Antiplatelet therapy prescribed for primary prevention of cardiovascular disease * Indication to maintain a dual-antiplatelet therapy. * Triple positive antiphospholipid syndrome, with arterial thrombosis * Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolic disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    28 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM - Hôpital la Timone

    RECRUITING

    Marseille, France

  • APHP - Hôpital Bicêtre

    RECRUITING

    Paris, France

  • APHP - Hôpital Européen Georges Pompidou HEGP

    RECRUITING

    Paris, France

  • APHP - Hôpital Louis Mourier

    RECRUITING

    Paris, France

  • CH Le Puy - Hôpital Emile Roux

    RECRUITING

    Le Puy-en-Velay, France

  • CH Toulon - Hôpital Sainte Musse

    RECRUITING

    Toulon, France

  • CH du Forez - Montbrison

    RECRUITING

    Montbrison, France

  • CH le Corbusier - Firminy

    RECRUITING

    Firminy, France

  • CHRU Brest - Hôpital la Cavale Blanche

    RECRUITING

    Brest, France

  • CHU Amiens

    RECRUITING

    Amiens, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Besançon - Hôpital Jean Minjoz

    RECRUITING

    Besançon, France

  • CHU Clermont-Ferrand - Hôpital Gabriel Montpied

    RECRUITING

    Clermont-Ferrand, France

  • CHU Dijon

    RECRUITING

    Dijon, France

  • CHU Grenoble - Hôpital la Tronche

    RECRUITING

    Grenoble, France

  • CHU Limoges

    RECRUITING

    Limoges, France

  • CHU Montpellier

    RECRUITING

    Montpellier, France

  • CHU Nancy - Hôpitaux de Brabois

    RECRUITING

    Nancy, France

  • CHU Nantes - Hôpital Hôtel-Dieu

    RECRUITING

    Nantes, France

  • CHU Rouen

    RECRUITING

    Rouen, France

  • CHU Saint-Etienne

    RECRUITING

    Saint-Etienne, France

  • CHU Strasbourg - Nouvel Hôpital Civil

    RECRUITING

    Strasbourg, France

  • CHU Toulouse - Hôpital de Rangueil

    RECRUITING

    Toulouse, France

  • CHU Tours

    RECRUITING

    Tours, France

  • CHU de Nice - Hôpital Pasteur

    RECRUITING

    Nice, France

  • Clinique du Parc - Castelnau-le -lez

    RECRUITING

    Castelnau-le-Lez, France

  • HCL - Hôpital Edouard Herriot

    RECRUITING

    Lyon, France

  • HCL - Lyon Sud

    RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.